Clinical trial
Phase II Single-arm "Window-of-opportunity" Study of a Combination of Obinutuzumab (GA-101) and Venetoclax (ABT-199) in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
NCT02987400 is registered in ClinicalTrials.gov with Arbeitsgemeinschaft medikamentoese Tumortherapie as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase II Single-arm "Window-of-opportunity" Study of a Combination of Obinutuzumab (GA-101) and Venetoclax (ABT-199) in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
- Lead sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- January 4, 2017
- Completion date
- October 19, 2021
- Enrollment
- 22 (actual)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.